Bivalirudin

Indications:

• As an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
• In patients undergoing percutaneous coronary intervention (PCI).
• For use in patients with, or at risk for, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).

Mechanism of Action: Bivalirudin directly inhibits thrombin, preventing its action on fibrinogen and its activation of platelets. This leads to a reduction in clot formation and platelet aggregation, providing anticoagulant effects.

Pharmacokinetics:

• Absorption: Administered intravenously, it acts rapidly.
• Distribution: Limited distribution, primarily in the bloodstream.
• Metabolism: Cleaved by proteolytic enzymes.
• Excretion: Renal excretion.

Form: Bivalirudin API is typically found as a white to off-white lyophilized powder.